LIX1L

LIX1L is an RNA-binding protein that functions as a post-transcriptional regulator of mRNA stability and miRNA expression, thereby controlling bile acid synthesis, glucose metabolism, lipid uptake, and ribosomal biogenesis. LIX1L binds AU-rich elements in target mRNAs such as CD36, stabilizing them to promote lipid accumulation and inflammation; this RNA-binding activity is enhanced by PARP1-mediated poly-ADP-ribosylation under metabolic stress (PMID:39725340). LIX1L also modulates miRNA levels—suppressing miR-191-3p to sustain bile acid synthesis via the LRH-1/CYP7A1 axis in cholestatic liver (PMID:33746084) and promoting miR-21-3p to repress FBP1 and drive glycolytic reprogramming in hepatocellular carcinoma (PMID:34221869). Beyond its RNA-regulatory roles, LIX1L interacts with nucleolin in the nucleolus to stimulate rRNA synthesis and epithelial–mesenchymal transition (PMID:36478492), and participates in a DCHS1–LIX1L–SEPT9 complex that organizes the actin cytoskeleton during cardiac valve morphogenesis (PMID:35200715).

1. 2015 Medium

   Establishing LIX1L as a novel RNA-binding protein and signaling hub resolved the basic molecular identity of a previously uncharacterized gene, revealing its capacity to bind double-stranded RNA, interact with RNA-processing proteins (NCL, PABPC4, RIOK1) and multiple miRNAs, and serve as a tyrosine-phosphorylation substrate whose phosphorylation at Tyr136 promotes cell proliferation.

   Evidence MALDI-TOF/TOF mass spectrometry, RIP-seq, kinase candidate screening, and homeodomain peptide inhibition assays in HEK-293 cells and xenograft models

   PMID:26310847

   Open questions at the time

   • No endogenous kinase validated as the physiological Tyr136 writer in a specific tissue context
   • Functional consequences of individual miRNA interactions not tested
   • Protein–protein interactions lack reciprocal validation in independent labs
2. 2021 High

   Demonstrating that LIX1L suppresses miR-191-3p to sustain bile acid synthesis answered how the liver coordinates post-transcriptional RNA regulation with metabolic output, establishing the Egr-1→LIX1L⊣miR-191-3p→LRH-1→CYP7A1/CYP8B1 axis in cholestasis.

   Evidence Lix1l knockout mice, miRNA microarray, AAV-mediated hepatic miR-191-3p delivery, BDL and Mdr2−/− cholestasis models, and ChIP for Egr-1 at the Lix1l promoter

   PMID:33746084

   Open questions at the time

   • Mechanism by which LIX1L suppresses miR-191-3p biogenesis or stability is unknown
   • Whether additional hepatic miRNAs are regulated by LIX1L beyond the array hits remains untested
3. 2021 Medium

   Showing that LIX1L upregulates miR-21-3p to repress FBP1 and reprogram glucose metabolism revealed a second, opposite-direction miRNA regulatory mode through which LIX1L drives the Warburg effect in hepatocellular carcinoma.

   Evidence LIX1L knockdown/overexpression in HCC cell lines, orthotopic tumor model, miR-21-3p inhibitor rescue, metabolic flux measurements

   PMID:34221869

   Open questions at the time

   • Direct binding of LIX1L to miR-21-3p precursor or processing machinery not demonstrated
   • Whether miR-191-3p and miR-21-3p regulation share a common mechanism is unknown
   • Single-lab observation without independent replication
4. 2022 Medium

   Identifying the LIX1L–nucleolin interaction in the nucleolus as a driver of rRNA synthesis during EMT expanded LIX1L's functional repertoire from cytoplasmic RNA regulation to nucleolar ribosome biogenesis.

   Evidence Co-immunoprecipitation, nucleolar localization imaging, NCL knockdown and rRNA synthesis inhibition in NSCLC cells

   PMID:36478492

   Open questions at the time

   • Whether LIX1L directly binds rDNA or rRNA precursors versus acting only through NCL is unresolved
   • No structural or domain-mapping data for the LIX1L–NCL interface
   • Single-lab co-IP without reciprocal pull-down from NCL side
5. 2022 Medium

   Placing LIX1L in a DCHS1–LIX1L–SEPT9 complex that organizes filamentous actin during mitral valve development revealed a non-RNA function linking cell adhesion to cytoskeletal morphogenesis.

   Evidence Co-immunoprecipitation, mouse valve tissue analysis, cell culture cytoskeletal organization assays

   PMID:35200715

   Open questions at the time

   • Direct binding surfaces between DCHS1, LIX1L, and SEPT9 are unmapped
   • Whether LIX1L's RNA-binding activity contributes to the valve phenotype is untested
   • Single-lab observation; phenotype in Lix1l conditional knockout valves not reported
6. 2024 High

   Demonstrating that PARP1-mediated poly-ADP-ribosylation stabilizes LIX1L and enhances its binding to AU-rich elements in CD36 mRNA resolved the post-translational mechanism coupling metabolic stress to LIX1L-driven lipid uptake and MASH pathogenesis.

   Evidence PARP1 inhibition, PARylation assays, Lix1l knockout mice, RNA-binding and mRNA half-life assays, MASH diet models

   PMID:39725340

   Open questions at the time

   • Specific PARylation sites on LIX1L are not mapped
   • Whether PARylation also modulates LIX1L's miRNA-regulatory activities is unknown
   • Genome-wide identification of direct LIX1L mRNA targets beyond CD36 has not been performed

• A unified model explaining how LIX1L simultaneously suppresses some miRNAs, promotes others, stabilizes specific mRNAs, and participates in cytoskeletal complexes—and whether these functions are coordinated through shared or distinct domains and post-translational modifications—remains to be established.
• No structural model or domain-function mapping exists for LIX1L
• Genome-wide direct RNA targets (CLIP-based) have not been defined
• Tissue-specific versus universal functions of LIX1L are uncharacterized